National CooperativeRx constantly monitors the pharmaceutical pipeline. As treatment options change, it’s important to know how those changes could impact your plan and which drugs bring the highest value. Our quarterly NCRx Pipeline Reports highlight some of the newest therapies coming to market and are not intended to imply formulary placement or coverage by CVS Caremark. SPN-812

National CooperativeRx constantly monitors the pharmaceutical pipeline. As treatment options change, it’s important to know how those changes could impact your plan and which drugs bring the highest value. Our quarterly NCRx Pipeline Reports highlight some of the newest therapies coming to market and are not intended to imply formulary placement or coverage by CVS

National CooperativeRx constantly monitors the pharmaceutical pipeline. As treatment options change, it’s important to know how those changes could impact your plan and which drugs bring the highest value. Our quarterly NCRx Pipeline Reports highlight some of the newest therapies coming to market and are not intended to imply formulary placement or coverage by CVS

It seems one can’t leave their house (or couch, these days!) without hearing the latest coronavirus (COVID-19) news. Although most of the updates are gloomy and unsettling, there is a glimmer of hope: drug trials have begun for a potential COVID-19 treatment. Read on to find the latest highlights and developments on the drug trials.

National CooperativeRx constantly monitors the pharmaceutical pipeline. As treatment options change, it’s important to know which drugs bring the highest value. Our quarterly NCRx Pipeline Reports provide insight from our clinical team on what changes you can expect to see on the market and how they impact plan performance. Vumerity™ (diroximel fumarate):  This medication is

National CooperativeRx constantly monitors the pharmaceutical pipeline. As treatment options change, it’s important to know which drugs bring the highest value. Our quarterly NCRx Pipeline Reports provide insight from our clinical team on what changes you can expect to see on the market and how they impact plan performance. Cequa® (cyclosporine): Cequa® is a new

National CooperativeRx constantly monitors the pharmaceutical pipeline. As treatment options change, it’s important to know which drugs bring the highest value. Our quarterly NCRx Pipeline Reports provide insight from our clinical team on what changes you can expect to see on the market and how they impact plan performance. Mayzent: Mayzent is the first treatment

National CooperativeRx constantly monitors the pharmaceutical pipeline for the latest drugs to share with our members. As treatment options change, it’s important to know which drugs bring the highest value, and that’s where we come in with our new quarterly NCRx Pipeline Reports. Gain access to insight on market changes and how they may impact